The two analyses, which represent AstraZeneca’s ongoing commitment to fully understanding the effects of dapagliflozin across subsets of patients with type 2 diabetes, will be presented at the ...

Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults. Dapagliflozin is also recommended for ...